GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference
March 10 2021 - 09:00AM
via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX), a
biotechnology company developing vaccines and immunotherapies
against infectious diseases and cancers, has been invited to
present at Maxim Group’s Inaugural Emerging Growth Virtual
Conference to be held March 17-18.
During this virtual conference, GeoVax’s Chairman and CEO, David
Dodd, will present an overview of GeoVax’s immunotherapy and
vaccine research and development efforts, focusing on the Company’s
COVID-19 and cancer immunotherapy programs. GeoVax’s Chief
Scientific Officer, Mark Newman, PhD, will also participate in a
panel discussion on recent developments in cancer vaccines and
immuno-oncology. Investors can view the presentation and the
panel by registering for the conference here and can also
request a 1x1 meeting with Mr. Dodd to be arranged following the
conclusion of the conference.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company
developing human vaccines against infectious diseases and cancer
using a novel patented Modified Vaccinia Ankara-Virus Like Particle
(MVA-VLP) based vaccine platform. On this platform, MVA, a large
virus capable of carrying several vaccine antigens, expresses
proteins that assemble into VLP immunogens in the person receiving
the vaccine. The production of VLPs in the person being vaccinated
can mimic virus production in a natural infection, stimulating both
the humoral and cellular arms of the immune system to recognize,
prevent, and control the target infection. The MVA-VLP derived
vaccines can elicit durable immune responses in the host similar to
a live-attenuated virus, while providing the safety characteristics
of a replication-defective vector.
GeoVax’s current development programs are focused on preventive
vaccines against COVID-19, HIV, Zika Virus, hemorrhagic fever
viruses (Ebola, Sudan, Marburg, and Lassa), and malaria, as well as
therapeutic vaccines against multiple cancers. The Company has
designed a preventive HIV vaccine candidate to fight against the
subtype of HIV prevalent in the commercial markets of the Americas,
Western Europe, Japan, and Australia; human clinical trials for
this program are managed by the HIV Vaccine Trials Network (HVTN)
with the support of the National Institutes of Health (NIH).
GeoVax’s HIV vaccine is also part of two separate collaborative
efforts to apply its innovative gene therapy approach toward a
functional cure for HIV.
GeoVax Labs, Inc. 6783847220 investor@geovax.com
GeoVax Labs (NASDAQ:GOVX)
Historical Stock Chart
From Feb 2024 to Mar 2024
GeoVax Labs (NASDAQ:GOVX)
Historical Stock Chart
From Mar 2023 to Mar 2024